New combo therapy hopes to boost lymphoma treatment
NCT ID NCT07138547
First seen Jan 11, 2026 · Last updated May 11, 2026 · Updated 20 times
Summary
This study tests whether adding the drug eliglustat to standard CD30-targeted immunotherapy can improve outcomes for people with CD30-positive lymphoma. About 40 adults who have already tried at least one other treatment will receive either a CAR-T cell therapy or an antibody-drug conjugate (brentuximab vedotin) combined with eliglustat. The main goals are to check safety and see if the combination leads to better tumor shrinkage or longer time without the disease getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
People's Liberation Army General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.